Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug/Software Combo Platform Coming Soon To US FDA, Gottlieb Says

Executive Summary

Under new platform, drugs could soon be approved with accompanying software applications that could monitor adverse events or patient compliance without a separate premarket device review.
Advertisement

Related Content

Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA
Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA
US FDA Mulling Core Criteria For Patient-Reported Outcomes
US FDA Preparing For New 'Combination Product Agreement Meetings'
US FDA Commish Defends Approach To Apple Approvals
US FDA's Digital Health Plan Could Brighten OTC Device Outlook
Combo-Product Sponsors Could More Easily Get Device Designation At US FDA
US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products
US FDA’s Patient Input Guidance Opens Door Wider To Social Media Data Collection
From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program

Topics

Advertisement
UsernamePublicRestriction

Register

PS124134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel